What has led to the change in the dose of nystatin oral suspension for treating oral and perioral candidal infections?
Until recently the BNF advised nystatin in a dose of 100 000 units 4 times daily for the treatment of candidal infections in patients of all ages. However, prompted by an enquiry to the BNF, clarification was sought from the marketing authorisation holder of Nystan Oral Suspension, Bristol-Myers Squibb. The company has confirmed that nystatin should be used for treating candidal infections only in individuals aged over 1 month (personal communication 6 December 2001).
Related Questions
- What has led to the change in the dose of nystatin oral suspension for treating oral and perioral candidal infections?
- When treating acute exacerbations, what dose of oral steroids is best and should the dose reduction be tapered?
- How is METACAM Oral Suspension administered? Can I dose directly from the syringe?
